Paul Tudor Jones Zentalis Pharmaceuticals, Inc. Transaction History
Tudor Investment Corp Et Al
- $26.8 Billion
- Q3 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 35,709 shares of ZNTL stock, worth $104,270. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,709Holding current value
$104,270% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding ZNTL
# of Institutions
142Shares Held
67.9MCall Options Held
48.5KPut Options Held
89.6K-
Matrix Capital Management Company, LP Waltham, MA14MShares$40.8 Million2.45% of portfolio
-
Eventide Asset Management, LLC Boston, MA8.55MShares$25 Million0.55% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$14.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.61MShares$13.5 Million0.0% of portfolio
-
Decheng Capital LLC Menlo Park, CA3.11MShares$9.08 Million2.71% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $166M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...